65.00
price down icon1.84%   -1.22
pre-market  Vorhandelsmarkt:  65.99   0.99   +1.52%
loading
Schlusskurs vom Vortag:
$66.22
Offen:
$65.2
24-Stunden-Volumen:
29,826
Relative Volume:
0.72
Marktkapitalisierung:
$2.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-55.36
EPS:
-1.1742
Netto-Cashflow:
-
1W Leistung:
+0.78%
1M Leistung:
+13.64%
6M Leistung:
+37.54%
1J Leistung:
+76.10%
1-Tages-Spanne:
Value
$64.18
$65.70
1-Wochen-Bereich:
Value
$64.18
$67.40
52-Wochen-Spanne:
Value
$31.00
$86.53

Belite Bio Inc Adr Stock (BLTE) Company Profile

Name
Firmenname
Belite Bio Inc Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
25
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-17
Name
Neueste SEC-Einreichungen
Name
BLTE's Discussions on Twitter

Vergleichen Sie BLTE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BLTE
Belite Bio Inc Adr
65.00 2.10B 0 -32.61M 0 -1.1742
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-12-14 Eingeleitet Maxim Group Buy
2023-07-28 Eingeleitet Cantor Fitzgerald Overweight
2023-07-26 Eingeleitet SVB Securities Outperform
2022-08-01 Eingeleitet H.C. Wainwright Buy
2022-07-01 Eingeleitet The Benchmark Company Buy

Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten

pulisher
Mar 28, 2025

Belite Bio, Inc. Appoints New Auditor - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Benchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

Belite Bio stock target raised to $80 at Benchmark By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Belite Bio price target raised to $80 from $79 at Benchmark - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Belite Bio stock target raised to $80 at Benchmark - Investing.com

Mar 26, 2025
pulisher
Mar 24, 2025

Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 21, 2025

Cantor Fitzgerald Forecasts Weaker Earnings for Belite Bio - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Belite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in February - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

HC Wainwright Has Pessimistic View of Belite Bio Q1 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Belite Bio’s Earnings Call: Cautious Optimism Amid Progress - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Belite Bio Announces 2025 Annual Shareholder Meeting - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Belite Bio stock holds $100 target post-results - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Belite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings Miss - Defense World

Mar 18, 2025
pulisher
Mar 18, 2025

Belite Bio Advances in Retinal Disease Trials and Financial Position - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

Earnings call transcript: Belite Bio ADR Q4 2024 sees steady R&D progress - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Belite Bio reports Q4 EPS (32c), consensus (31c) - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Belite Bio Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - Markets Insider

Mar 17, 2025
pulisher
Mar 17, 2025

Belite Bio Releases 2024 Annual Report on Website - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Belite Bio Reports Positive Interim Analysis Results for Phase 3 DRAGON Trial and Financial Update for Q4 2024 - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Public market insider buying at Savaria (SIS) - The Globe and Mail

Mar 17, 2025
pulisher
Mar 17, 2025

Belite Bio's $145M War Chest Powers Critical Phase 3 Eye Disease Trial - StockTitan

Mar 17, 2025
pulisher
Mar 16, 2025

Belite Bio (NASDAQ:BLTE) Trading Down 1.6% – Time to Sell? - Defense World

Mar 16, 2025
pulisher
Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail

Mar 12, 2025
pulisher
Mar 11, 2025

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian

Mar 11, 2025
pulisher
Mar 11, 2025

Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - StockTitan

Mar 11, 2025
pulisher
Mar 07, 2025

Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail

Mar 07, 2025
pulisher
Mar 05, 2025

Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail

Mar 05, 2025
pulisher
Mar 04, 2025

Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail

Mar 04, 2025
pulisher
Mar 04, 2025

Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan

Mar 04, 2025
pulisher
Mar 03, 2025

2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail

Mar 03, 2025
pulisher
Feb 28, 2025

Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Belite Bio Announces Interim Analysis Results from the - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - StockTitan

Feb 27, 2025
pulisher
Feb 25, 2025

Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat

Feb 25, 2025
pulisher
Feb 23, 2025

Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume – Still a Buy? - The AM Reporter

Feb 23, 2025
pulisher
Feb 20, 2025

Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat

Feb 20, 2025
pulisher
Feb 16, 2025

Belite Bio (NASDAQ:BLTE) Stock Price Up 7.8%Should You Buy? - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

Belite Bio (NASDAQ:BLTE) Shares Down 4.7%Time to Sell? - MarketBeat

Feb 14, 2025
pulisher
Feb 10, 2025

Advisors Preferred LLC Purchases New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Armenian Reporter

Feb 10, 2025
pulisher
Feb 06, 2025

Belite Bio Announces $15 Million Direct Offering to Enhance Financial Position - TipRanks

Feb 06, 2025
pulisher
Feb 06, 2025

BLTEBelite Bio, Inc Latest Stock News & Market Updates - StockTitan

Feb 06, 2025
pulisher
Feb 05, 2025

Sangoma Announces Second Quarter Fiscal 2025 Results - The Globe and Mail

Feb 05, 2025
pulisher
Feb 05, 2025

Why Oklo Stock Jumped 96% in January - The Globe and Mail

Feb 05, 2025

Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Kapitalisierung:     |  Volumen (24h):